BIO-PATH HOLDINGS INC (BPTH) Stock Price & Overview
NASDAQ:BPTH • US09057N4097
Current stock price
The current stock price of BPTH is 0.21 USD. Today BPTH is down by -66.84%. In the past month the price decreased by -74.39%. In the past year, price decreased by -96.41%.
BPTH Key Statistics
- Market Cap
- 905.1K
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -13.79
- Dividend Yield
- N/A
BPTH Stock Performance
BPTH Stock Chart
BPTH Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to BPTH. When comparing the yearly performance of all stocks, BPTH is a bad performer in the overall market: 99.4% of all stocks are doing better.
BPTH Earnings
BPTH Forecast & Estimates
7 analysts have analysed BPTH and the average price target is 12.24 USD. This implies a price increase of 5728.57% is expected in the next year compared to the current price of 0.21.
BPTH Groups
Sector & Classification
BPTH Financial Highlights
Over the last trailing twelve months BPTH reported a non-GAAP Earnings per Share(EPS) of -13.79. The EPS increased by 66.03% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -354.57% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BPTH Ownership
BPTH Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.02 | 369.265B | ||
| AMGN | AMGEN INC | 15.08 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.84 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.69 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.41 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.08 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 10.91 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.74 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.51 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BPTH
Company Profile
Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). The company is headquartered in Bellaire, Texas and currently employs 10 full-time employees. The company went IPO on 2006-01-11. The firm is engaged in developing DNAbilize, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. Its lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase II study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase I/Ib study for solid tumors. The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. BP1003 is its third liposome delivered antisense drug candidate.
Company Info
IPO: 2006-01-11
BIO-PATH HOLDINGS INC
4710 Bellaire Boulevard, Suite 210
Bellaire TEXAS 77401 US
CEO: Peter H. Nielsen
Employees: 10
Phone: 18327421357
BIO-PATH HOLDINGS INC / BPTH FAQ
Can you describe the business of BIO-PATH HOLDINGS INC?
Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). The company is headquartered in Bellaire, Texas and currently employs 10 full-time employees. The company went IPO on 2006-01-11. The firm is engaged in developing DNAbilize, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. Its lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase II study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase I/Ib study for solid tumors. The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. BP1003 is its third liposome delivered antisense drug candidate.
What is the current price of BPTH stock?
The current stock price of BPTH is 0.21 USD. The price decreased by -66.84% in the last trading session.
Does BIO-PATH HOLDINGS INC pay dividends?
BPTH does not pay a dividend.
What is the ChartMill rating of BIO-PATH HOLDINGS INC stock?
BPTH has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the next earnings date for BPTH stock?
BIO-PATH HOLDINGS INC (BPTH) will report earnings on 2025-03-07, after the market close.
What is the Short Interest ratio of BIO-PATH HOLDINGS INC (BPTH) stock?
The outstanding short interest for BIO-PATH HOLDINGS INC (BPTH) is 0.04% of its float.